4 results
S-1/A
EX-10.16
SHPH
Shuttle Pharmaceuticals Holdings Inc
23 Jun 22
IPO registration (amended)
5:24pm
vivo culture of epithelial cells, specifically employing Conditional Reprogramming (“CR”) technology.
WHEREAS, Georgetown has granted exclusive … the CR Technology. CR reagents include (but are not limited to) cell culture media (CRM), irradiated 3T3-J2 cells, irradiated 3T3-J2 cell conditioned
S-1/A
EX-10.8
SHPH
Shuttle Pharmaceuticals Holdings Inc
23 Jun 22
IPO registration (amended)
5:24pm
.
Milestone 2.2. Proprietary formula of growth factors needed to promote AA CRC culture growth.
Page 1
ATTACHMENT 1
Statement of Work (Phase I) Dated 09
S-1/A
EX-10.17
SHPH
Shuttle Pharmaceuticals Holdings Inc
23 Jun 22
IPO registration (amended)
5:24pm
we propose to manufacture TMAs from our annotated prostate epithelial cell culture.
Task 2.1. Based on prostate epithelial cell annotation data
DRS
SHPH
Shuttle Pharmaceuticals Holdings Inc
16 Sep 19
Draft registration statement
12:00am
included a subcontract with Georgetown University for use of a tissue culture core facility for growing human prostate cells derived from African … of a tissue culture core facility for growing human prostate cells derived from African-American donors. At completion of the Phase I effort, the company
- Prev
- 1
- Next